Patents by Inventor Li Bovet
Li Bovet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9808423Abstract: The present invention provides processes for preparing suspension aerosol formulations, wherein the particles for inhalation are formed in situ during the process of manufacturing the formulation. In one aspect of the invention, a process for preparing a suspension aerosol formulation comprises the steps of: (a) dissolving one or more medicaments in one or more solvents to form a solution; and (b) mixing one or more propellants with the solution under conditions effective to precipitate, entirely or partially, at least one of the medicaments.Type: GrantFiled: October 12, 2005Date of Patent: November 7, 2017Assignee: Generics [UK] LimitedInventors: Li Li Bovet, Jay T. Holt
-
Publication number: 20090297457Abstract: The present invention provides processes for preparing suspension aerosol formulations, wherein the particles for inhalation are formed in situ during the process of manufacturing the formulation. In one aspect of the invention, a process for preparing a suspension aerosol formulation comprises the steps of: (a) dissolving one or more medicaments in one or more solvents to form a solution; and (b) mixing one or more propellants with the solution under conditions effective to precipitate, entirely or partially, at least one of the medicaments.Type: ApplicationFiled: October 12, 2005Publication date: December 3, 2009Applicant: GENERICS [UK] LIMITEDInventors: Li Li Bovet, Jay T. Holt
-
Publication number: 20070243262Abstract: The invention provides stable S-nitrosothiol, such as S-nitrosoglutathione, formulations for long term storage and in vivo delivery of S-nitrosothiols. The invention provides stable aerosol formulations comprising S-nitrosothiol, such as S-nitrosoglutathione, and methods of treating patients in need of S-nitrosothiol, such as S-nitrosoglutathione, and/or nitric oxide treatment.Type: ApplicationFiled: December 21, 2006Publication date: October 18, 2007Inventors: Kevin Hurley, Li Bovet, Jonathan Stamler
-
Patent number: 7196059Abstract: Pharmaceutical compositions that include insulin, an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component or a bile salt component without a fatty acid component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.Type: GrantFiled: March 5, 2003Date of Patent: March 27, 2007Assignee: Biocon LimitedInventors: Richard Soltero, Balasingam Radhakrishan, Nnochiri N. Ekwuribe, Bruce Rehlaender, Anthony Hickey, Li Li Bovet
-
Patent number: 7030082Abstract: Pharmaceutical compositions that include a drug and/or drug-oligomer conjugate, a fatty acid component and a bile salt component, or a bile salt component without a fatty acid component are described. The drug can be covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1 or any value between. Methods of treating diseases in a subject in need of such treatment using the pharmaceutical compositions of this invention are also provided, as well as methods of providing such pharmaceutical compositions.Type: GrantFiled: March 5, 2003Date of Patent: April 18, 2006Assignee: Nobex CorporationInventors: Richard Soltero, Nnochiri N. Ekwuribe, Foyeke Opawale, Bruce Rehlaender, Anthony Hickey, Li Li Bovet
-
Patent number: 6867183Abstract: Pharmaceutical compositions that include an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.Type: GrantFiled: September 5, 2002Date of Patent: March 15, 2005Assignee: Nobex CorporationInventors: Richard Soltero, Balasingam Radhakrishan, Nnochiri N. Ekwuribe, Bruce Rehlaender, Anthony Hickey, Li Li Bovet
-
Publication number: 20050002869Abstract: A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising beclomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.Type: ApplicationFiled: July 21, 2004Publication date: January 6, 2005Applicant: SmithKline Beecham CorporationInventors: Ian Ashurst, Craig Herman, Li Li-Bovet, Michael Riebe
-
Publication number: 20040223919Abstract: A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising beclomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.Type: ApplicationFiled: June 10, 2004Publication date: November 11, 2004Applicant: SmithKline Beecham CorporationInventors: Ian C. Ashurst, Ignatius Loy Britto, Craig Steven Herman, Li Li-Bovet, Michael Thomas Riebe
-
Publication number: 20040187865Abstract: A metered dose inhaler having all or part of its internal surfaces coated with one or more fluorocarbon polymers, optimally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formation comprising fluticasone propionate or a physiologically acceptable solvate thereof and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.Type: ApplicationFiled: April 14, 2004Publication date: September 30, 2004Applicant: SmithKline Beecham Corp.Inventors: Ian C. Ashurst, Ignatius Loy Britto, Craig Steven Herman, Li Li-Bovet, Michael Thomas Riebe
-
Patent number: 6770625Abstract: Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.Type: GrantFiled: September 5, 2002Date of Patent: August 3, 2004Assignee: Nobex CorporationInventors: Richard Soltero, Nnochiri N. Ekwuribe, Foyeke Opawale, Bruce Rehlaender, Anthony Hickey, Li Li Bovet
-
Publication number: 20040086464Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation. More particularly, the invention relates to a pharmaceutical aerosol formulation which comprises particulate salbutamol sulphate having a crystalline form in which the outer layer of the crystals is substantially non-amorphous; and 1,1,1,2-tetrafluoroethane. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: ApplicationFiled: October 27, 2003Publication date: May 6, 2004Inventors: Michael Thomas Riebe, Sarvajna Kumar Dwivedi, Li Li-Bovet
-
Publication number: 20040038866Abstract: Pharmaceutical compositions that include insulin, an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component or a bile salt component without a fatty acid component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.Type: ApplicationFiled: March 5, 2003Publication date: February 26, 2004Inventors: Richard Soltero, Balasingam Radhakrishnan, Nnochiri N. Ekwuribe, Bruce Rehlaender, Anthony Hickey, Li Li Bovet
-
Publication number: 20040017387Abstract: Pharmaceutical compositions that include a drug and/or drug-oligomer conjugate, a fatty acid component and a bile salt component, or a bile salt component without a fatty acid component are described. The drug can be covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1 or any value between. Methods of treating diseases in a subject in need of such treatment using the pharmaceutical compositions of this invention are also provided, as well as methods of providing such pharmaceutical compositions.Type: ApplicationFiled: March 5, 2003Publication date: January 29, 2004Inventors: Richard Soltero, Nnochiri N. Ekwuribe, Foyeke Opawale, Bruce Rehlaender, Anthony Hickey, Li Li Bovet
-
Patent number: 6656453Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation. More particularly, the invention relates to a pharmaceutical aerosol formulation which comprises particulate salbutamol sulphate having a crystalline form in which the outer layer of the crystals is substantially non-amorphous; and 1,1,1,2-tetrafluoroethane. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: June 27, 2002Date of Patent: December 2, 2003Assignee: SmithKline Beecham CorporationInventors: Michael Thomas Riebe, Sarvajna Kumar Dwivedi, Li Li-Bovet
-
Publication number: 20030138559Abstract: A metered dose inhaler having all or part of its internal surfaces coated with one or more fluorocarbon polymers, optimally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formation comprising albuterol or a physiologically acceptable salt thereof and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.Type: ApplicationFiled: February 3, 2003Publication date: July 24, 2003Applicant: SmithKline Beecham CorporationInventors: Ian C. Ashurst, Ignatius Loy Britto, Craig Steven Herman, Li Li-Bovet, Michael Thomas Riebe
-
Publication number: 20030103906Abstract: A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising beclomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.Type: ApplicationFiled: December 16, 2002Publication date: June 5, 2003Applicant: SmithKline Beecham CorporationInventors: Ian C. Ashurst, Ignatius Loy Britto, Craig Steven Herman, Li Li-Bovet, Michael Thomas Riebe
-
Patent number: 6558651Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation. More particularly, the invention relates to a pharmaceutical aerosol formulation which comprises particulate salbutamol sulphate having a crystalline form in which the outer layer of the crystals is substantially non-amorphous; and 1,1,1,2-tetrafluoroethane. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: June 18, 1998Date of Patent: May 6, 2003Assignee: SmithKline Beecham CorporationInventors: Michael Thomas Riebe, Sarvajna Kumar Dwivedi, Li Li-Bovet
-
Publication number: 20030083232Abstract: Pharmaceutical compositions that include an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.Type: ApplicationFiled: September 5, 2002Publication date: May 1, 2003Inventors: Richard Soltero, Balasingham Radhakrishnan, Nnochiri N. Ekwuribe, Bruce Rehlander, Anthony Hickey, Li Li Bovet
-
Patent number: 6546928Abstract: A metered dose inhaler having all or part of its internal surfaces coated with one or more fluorocarbon polymers, optimally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formation comprising albuterol or a physiologically acceptable salt thereof and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.Type: GrantFiled: May 15, 2000Date of Patent: April 15, 2003Assignee: SmithKline Beecham CorporationInventors: Ian C. Ashurst, Ignatius Loy Britto, Craig Steven Herman, Li Li-Bovet, Michael Thomas Riebe
-
Patent number: 6532955Abstract: A metered dose inhaler having all or part of its internal surfaces coated with one or more fluorocarbon polymers, optimally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formation comprising fluticasone propionate or a physiologically acceptable solvate thereof and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.Type: GrantFiled: May 15, 2000Date of Patent: March 18, 2003Assignee: SmithKline Beecham CorporationInventors: Ian C. Ashurst, Ignatius Loy Britto, Craig Steven Herman, Li Li-Bovet, Michael Thomas Riebe